Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Metabolomics for Prediction of Relapse in Graves' Disease: Observational Pilot Study.

Struja T, Eckart A, Kutz A, Huber A, Neyer P, Kraenzlin M, Mueller B, Meier C, Bernasconi L, Schuetz P.

Front Endocrinol (Lausanne). 2018 Oct 17;9:623. doi: 10.3389/fendo.2018.00623. eCollection 2018.

2.

Comparison of Five TSH-Receptor Antibody Assays in Graves' disease: results from an observational pilot study.

Struja T, Jutzi R, Imahorn N, Kaeslin M, Boesiger F, Kutz A, Mundwiler E, Huber A, Kraenzlin M, Mueller B, Meier C, Bernasconi L, Schuetz P.

BMC Endocr Disord. 2019 Apr 25;19(1):38. doi: 10.1186/s12902-019-0363-6.

3.

Metabolomics and Their Ability to Distinguish Thyroid Disorders: A Retrospective Pilot Study.

Struja T, Eckart A, Kutz A, Neyer P, Kraenzlin M, Mueller B, Meier C, Bernasconi L, Schuetz P.

Horm Metab Res. 2019 Apr;51(4):256-260. doi: 10.1055/a-0850-9691. Epub 2019 Feb 21.

PMID:
30791054
4.

External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients.

Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A, Bernasconi L, Mundwiler E, Mueller B, Christ-Crain M, Meienberg F, Ebrahimi F, Henzen C, Fischli S, Kraenzlin M, Meier C, Schuetz P.

Eur J Endocrinol. 2017 Apr;176(4):413-419. doi: 10.1530/EJE-16-0986. Epub 2017 Jan 18.

PMID:
28100628
5.

Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Langenstein C, Schork D, Badenhoop K, Herrmann E.

Rev Endocr Metab Disord. 2016 Dec;17(4):571-581. doi: 10.1007/s11154-016-9386-8. Review.

PMID:
27638651
6.

Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.

Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE; Basedow Study Group.

Thyroid. 2005 Sep;15(9):1047-54.

PMID:
16187913
7.

High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months.

Hwang S, Shin DY, Song MK, Lee EJ.

Endocrine. 2015 Feb;48(1):89-95. doi: 10.1007/s12020-014-0325-8. Epub 2014 Jun 27.

PMID:
24968734
8.

Thyroid blood flow as a useful predictor of relapse of Graves' disease after normal delivery in patients with Graves' disease.

Nagasaki T, Inaba M, Fujiwara-Ueda M, Nishio J, Kumeda Y, Hiura Y, Tahara H, Ishimura E, Ishiko O, Nishizawa Y.

Biomed Pharmacother. 2010 Feb;64(2):113-7. doi: 10.1016/j.biopha.2009.04.038. Epub 2009 Oct 20.

PMID:
20006462
9.

Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.

Liu X, Shi B, Li H.

Ann Endocrinol (Paris). 2015 Dec;76(6):679-83. doi: 10.1016/j.ando.2015.08.004. Epub 2015 Oct 27.

PMID:
26514949
10.

Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?

Zingrillo M, D'Aloiso L, Ghiggi MR, Di Cerbo A, Chiodini I, Torlontano M, Liuzzi A.

Clin Endocrinol (Oxf). 1996 Aug;45(2):201-6.

PMID:
8881453
11.

Mean Platelet Volume in Graves' disease: A Sign of Hypermetabolism Rather than Autoimmunity?

Bagir GS, Haydardedeoglu FE, Bakiner OS, Bozkirli E, Ertorer ME.

Pak J Med Sci. 2017 Jul-Aug;33(4):871-875. doi: 10.12669/pjms.334.12659.

12.

[Evaluation of the medical treatment of Graves' disease (GD)].

Peixoto MC, Coeli CM, Vaisman M.

Arq Bras Endocrinol Metabol. 2005 Jun;49(3):410-9. Epub 2006 Mar 16. Portuguese.

PMID:
16543996
13.

Physiological and Metabolic Changes During the Transition from Hyperthyroidism to Euthyroidism in Graves' Disease.

Chng CL, Lim AY, Tan HC, Kovalik JP, Tham KW, Bee YM, Lim W, Acharyya S, Lai OF, Chong MF, Yen PM.

Thyroid. 2016 Oct;26(10):1422-1430. Epub 2016 Sep 7.

PMID:
27465032
14.

Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.

Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U.

Eur J Endocrinol. 2002 Feb;146(2):173-7.

PMID:
11834425
15.

Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.

Schott M, Minich WB, Willenberg HS, Papewalis C, Seissler J, Feldkamp J, Bergmann A, Scherbaum WA, Morgenthaler NG.

Horm Metab Res. 2005 Dec;37(12):741-4.

PMID:
16372227
16.

Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid diseases.

Zhu Y, Portmann L, Dénéréaz N, Lemarchand-Béraud T.

Eur J Endocrinol. 1994 Oct;131(4):359-68.

PMID:
7921224
18.

Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.

Gómez-Arnaiz N, Andía E, Gumà A, Abós R, Soler J, Gómez JM.

Horm Metab Res. 2003 Aug;35(8):492-7.

PMID:
12953167
19.

Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves' disease.

Mizuguchi Y, Morimoto S, Kimura S, Takano N, Yamashita K, Seki Y, Bokuda K, Yatabe M, Yatabe J, Watanabe D, Ando T, Ichihara A.

PLoS One. 2018 Apr 5;13(4):e0195464. doi: 10.1371/journal.pone.0195464. eCollection 2018.

20.

Supplemental Content

Support Center